Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 28 January 2021, 09:50 HKT/SGT
Share:
China Biotech Services LY007 Cell Injection Obtained Clinical Trial Approval Letter
China's first and only CAR-T product with CD20 target approved for registration clinical application

HONG KONG, Jan 28, 2021 - (ACN Newswire) - China Biotech Services Holdings Limited ("CH BIOTECH SER" or "Company", stock code: 8037.HK) non-wholly-owned subsidiary Shanghai Longyao Biotechnology Co., Ltd. ( "Shanghai Longyao") received an approval letter from the National Medical Products Administration for a clinical trial of the Company's LY007 Cellular Injection on January 21, 2021, which is registered as a Class I new drug. LY007 Cellular Injection is mainly used for the treatment of non-Hodgkin lymphoma. It is currently the first and only CD20-targeted CAR-T product whose application for a registered clinical trial has been approved in China.

LY007 Cellular Injection is a chimeric antigen receptor T-cell (CAR-T) injection and is mainly used in the treatment of relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma and metastatic follicular lymphoma. LY007 Cellular Injection has beenwas developed independently by Shanghai Longyao and incorporates its patented OX40 co-stimulatory signal design. Experiments have proved that the design enhances the efficacy of the Product without compromising safety. According to the clinical trial application of LY007 Cellular Injection, Shanghai Longyao will commence Phase I clinical trial and study of LY007 Cellular Injection based on the submitted proposal.The National Medical Products Administration's approval of Shanghai Longyao's clinical trial application for LY007 Cellular Injection demonstrates Shanghai Longyao's capabilities in the research and development of immunocellular drugs.

According to a research report issued by China Merchants Bank on CH BIOTECH SER on November 20, 2020, the analyst recommended to watch for the results of the LY007 Cellular Injection clinical trial which could enhance the company's market value. The report also pointed out that the company's current market capitalization is slightly less than US$200 million while market capitalization of CAR-T comparable companies listed on the main board of the Hong Kong Stock Exchange is between US$600 million and US$1.4 billion. The current market value of CAR-T comparable Chinese companies listed on NASDAQ is approximately US$3.5 billion.




Topic: Press release summary
Sectors: Daily Finance, Daily News, BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2021 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Latest Press Releases
UREEQA Welcomes Dean Drever, a Sculptor Who Has Produced Multi-Million Dollar Works of Art  
Mar 6, 2021 23:00 HKT/SGT
Tianyun International: Rainbow Lead Ventures Limited Becomes a New Strategic Shareholder of the Group  
Mar 6, 2021 14:10 HKT/SGT
Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the 15th International Conference on Alzheimer's and Parkinson's Disease  
Mar 5, 2021 16:51 HKT/SGT
CUPNOODLES MUSEUM HONG KONG BY NISSIN FOODS SET FOR LAUNCH   
Mar 5, 2021 12:53 HKT/SGT
Moonstake Partners with P2P Escrow Service Escaroo  
Mar 5, 2021 12:30 HKT/SGT
MHI Group Presents "Best Innovation 2020" Awards for Activities that Contribute to Reducing Environmental Loads  
Mar 5, 2021 08:30 HKT/SGT
CoinSmart Closes CAD$4.5 Million Seed Funding; Plans to Expand into Europe   
Mar 5, 2021 08:17 HKT/SGT
China Gas Enters into Strategic Cooperation Framework Agreement with Sinopec  
Mar 4, 2021 21:22 HKT/SGT
Acquiring Xiaoer Qingre Zhike granule, Tianda Pharmaceuticals continues to broaden its product mix and perfect its Chinese medicine whole industry chain layout  
Mar 4, 2021 19:43 HKT/SGT
Billboard Hot 100 #1 Hit of the Year Band Member Partners with UREEQA  
Mar 4, 2021 18:50 HKT/SGT
More Press release >>
 Events:
More >>
 News Alerts
Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: